Torren Management’s Bristol-Myers Squibb BMY Stock Holding History

Torren Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14	Closed	-$755	–	1056
2025 Q4	$755	Buy	+14	New	+$674	﹤0.01%	1261

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Torren Management's BMY Position: Q1 2026 in Review

Torren Management sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 14 shares — an estimated $755 sold.

Torren Management first reported a position in BMY in Q4 2025 and held it in 1 quarter. The position peaked at $755 in Q4 2025. 2,526 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Torren Management reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
Torren Management sold 14 Bristol-Myers Squibb shares in Q1 2026, an estimated $755.
Torren Management first reported a position in Bristol-Myers Squibb in Q4 2025 and held it in 1 quarter.
Torren Management's Bristol-Myers Squibb position peaked at $755 in Q4 2025.
2,526 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.